Who
George Magrath
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Opus Genetics.
In numbers
- Trades disclosed
- 30
- Buys
- 5
- Sells
- 4
- Bought
- $257K
- Sold
- $444K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Nov 2023
- Last trade
- 23 Oct 2026
- Last filed
- 27 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Oct 2026filed 27 Oct 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $34K9,591 at $3.59 | filing |
| 9 Sep 2026filed 11 Sep 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code M | $451K392,157 at $1.15 | filing |
| 9 Sep 2026filed 11 Sep 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $451K75,541 at $5.97 | filing |
| 9 Sep 2026filed 11 Sep 2026 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —392,157 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —392,157 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code M | $451K392,157 at $1.15 | filing |
| 9 Sep 2026filed 11 Sep 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $451K75,541 at $5.97 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $28K9,475 at $2.95 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $28K9,475 at $2.95 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $50K9,511 at $5.22 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $50K9,511 at $5.22 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $127K24,438 at $5.21 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $127K24,438 at $5.21 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —483,639 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —483,639 at $0.00 | filing |
| 1 Nov 2025filed 5 Nov 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $70K30,350 at $2.30 | filing |
| 1 Nov 2025filed 4 Nov 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $70K30,350 at $2.30 | filing |
| 24 Mar 2025filed 26 Mar 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —392,157 | filing |
| 24 Mar 2025filed 26 Mar 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —392,157 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,697 at $0.00 | filing |
News
Opus Genetics (NASDAQ:IRD) vs. Alkermes (NASDAQ:ALKS) Financial AnalysisIRD · dailypolitical.com · 26 Oct 2026Head to Head Review: Alkermes (NASDAQ:ALKS) and Opus Genetics (NASDAQ:IRD)IRD · tickerreport.com · 26 Oct 2026Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood BlindnessIRD · manilatimes.net · 21 Oct 2026
0 headlines in the last 90 days name George Magrath; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.